Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients

Darleen R Powars, Linda S Chan, Alan Hiti, Emily Ramicone, Cage Johnson, Darleen R Powars, Linda S Chan, Alan Hiti, Emily Ramicone, Cage Johnson

Abstract

Based on a prospective cohort study of 1056 patients with sickle cell anemia (Hb SS) initiated in 1959, we investigated the influence of calendar era, age, sex, and prior medical conditions on the subsequent development of irreversible organ damage and survival using the Cox regression model with time-dependent covariates adjusting for all prior occurrences. We studied 30 acute clinical events, and focused on 8 prototypic forms of irreversible organ damage. Childhood survival to age 20 years has improved from 79% for those born before 1975 to 89% for children born in or after 1975. Bone infarction was a significant risk factor for avascular necrosis (p = 0.01), and infantile dactylitis was a significant risk factor for stroke (p = 0.01). Prior hospitalized vaso-occlusive sickle crisis in adults was significantly associated with the increased rate of avascular necrosis (p < 0.001), leg ulcers (p < 0.001), sickle chronic lung disease (p < 0.001), renal failure (p < 0.005), and early death (p < 0.001). The diagnosis of clearly evident clinical conditions such as leg ulcer, osteonecrosis, and retinopathy predicted an increased likelihood of developing a more lethal form of organ damage and earlier death: 77% of patients with chronic lung disease, 75% of those with renal insufficiency, and 51% of those with stroke had a prior chronic condition. Of the 232 patients who died, 73% had 1 or more clinically recognized forms of irreversible organ damage. By the fifth decade, nearly one-half of the surviving patients (48%) had documented irreversible organ damage. End-stage renal disease (glomerulosclerosis), chronic pulmonary disease with pulmonary hypertension, retinopathy, and cerebral microinfarctions are manifestations of arterial and capillary microcirculation obstructive vasculopathy. The current study underscores the need for preventive therapy to ameliorate the progression of the sickle vasculopathy.

References

    1. Acquaye JK, Omer A, Ganeshaguru K, Sejeny A, Hoffbrand AV. Non-benign sickle cell anaemia in Western Saudi Arabia. Br J Haematol. 1985;60:99-108.
    1. Adamkiewicz TV, Mehta PS, Boyer MW, Kedar A, Olson TA, Olson E, Chiang KY, Maurer D, Mogul MJ, Wingard JR, Yeager AM. Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. Bone Marrow Trans. 2004;34:405-411.
    1. Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, Rogers ZR, Vichinsky E, Elliott J, Facklam RR, O'Brien KL, Schwartz B, Van Beneden CA, Cannon MJ, Eckman JR, Keyserling H, Sullivan K, Wong WY, Wang WC. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr. 2003;143:438-444.
    1. Adams RJ. Stroke prevention and treatment in sickle cell disease. Arch Neurol. 2001;58:565-568.
    1. Anson JA, Koshy M, Ferguson L, Crowell RM. Subarachnoid hemorrhage in sickle-cell disease. J Neurosurg. 1991;75:552-558.
    1. Aslan M, Ryan TM, Townes TM, Coward L, Kirk MC, Barnes S, Alexander CB, Rosenfeld SS, Freeman BA. Nitric oxide-dependent generation of reactive species in sickle cell disease. J Biol Chem. 2003;278:4194-4204.
    1. Atkins RC, Walters MC. Haematopoietic cell transplantation in the treatment of sickle cell disease. Expert Opin Biol Ther. 2003;3:1215-1224.
    1. Bakanay SM, Dainer E, Clair B, Adekile A, Daitch L, Wells L, Holley L, Smith D, Kutlar A. Mortality in sickle cell patients on hydroxyurea therapy. Blood. 2005;105:545-547.
    1. Ballas SK, Marcolina MJ, Dover GJ, Barton FB. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. Br J Haematol. 1999;105:491-496.
    1. Berry G. The analysis of mortality by the subject-years method. Biometrics. 1984;39:173-184.
    1. Bhalla M, Abbond MR, McLoud TC, Shepard JO, Munden MM, Jackson SM, Beaty JR, Laver JH. Acute chest syndrome in sickle cell disease: CT evidence of microvascular occlusion. Radiology. 1993;187:45-49.
    1. Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F. Post licensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001;20:1105-1107.
    1. Breslow NE. Elementary methods of cohort analysis. Int J Epidemiol. 1984;13:112-115.
    1. Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood. 2003;101:1257-1261.
    1. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore). 1996;75:300-326.
    1. Charache S. Who should get HU? And how? Blood. 2002;99:1.
    1. Cheung ATW, Chen PCY, Larkin EC, Duong PL, Ramanujam S, Tablin F, Wun T. Microvascular abnormalities in sickle cell disease: a computer-assisted intravital microscopy study. Blood. 2002;99:3999-4005.
    1. Cohen AR. Sickle cell disease-new treatments, new questions. N Engl J Med. 1998;339:42-44.
    1. Davis H, Gergen PJ, Moore RM. Geographic differences in mortality of young children with sickle cell disease in the United States. Public Health Rep. 1997;112:52-58.
    1. Davis H, Schoendorf KC, Gergen PJ, Moore RM. National trends in the mortality of children with sickle cell disease: 1968 through 1992. Am J Public Health. 1997;87:1317-1322.
    1. DeSimone J, Koshy M, Dorn L, Lavelle D, Bressier L, Molokie R, Talischy N. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle anemia. Blood. 2002;99:3905-3908.
    1. Donnelly PK, Edmunds ME, O'Reilly K. Renal transplantation in sickle cell disease. Lancet. 1988;110:229.
    1. Ewing NP, Powars DR, Hilburn J, Schroeder WA. Newborn diagnosis of abnormal hemoglobins from a large municipal hospital in Los Angeles. Am J Pub Health. 1981;71:629-631.
    1. Fauroux B, Muller MH, Quinet B, Begue P. [The sickle cell anemia lung from childhood to adulthood.] Rev Mal Respir. 1998;15:159-168.
    1. Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, Devalck C, Dresse MF, Feremans W, Hunninck K, Toppet M, Philippet P, Van Geet C, Sariban E. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97:3628-3632.
    1. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, Vichinsky E, Iyer R, Lobel JS, Diamond S, Holbrook CT, Gill FM, Ritchey K, Falletta JM. Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med. 1986;314:1593-1599.
    1. Gelpi AP. Benign sickle cell disease in Saudi Arabia: survival estimate and population dynamics. Clin Genet. 1979;15:307-310.
    1. Gladwin MT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nature Med. 2003;9:496-500.
    1. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886-895.
    1. Gupta R, Adekile AD. MRI follow-up and natural history of avascular necrosis of the femoral head in Kuwaiti children with sickle cell disease. J Pediatr Hematol Oncol. 2004;26:351-353.
    1. Hanker GJ, Amstutz HC. Osteonecrosis of the hip in the sickle-cell diseases. J Bone Joint Surg. 1988;70:499-506.
    1. Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med. 1994;96:155-162.
    1. Henderson JN, Noetzel MJ, McKinstry RC, White DA, Armstrong M, DeBaun MR. Reversible posterior leukoencephalopathy syndrome and silent cerebral infarcts are associated with severe acute chest syndrome in children with sickle cell disease. Blood. 2003;101:415-419.
    1. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol. 2000;322-327.
    1. Hord J, Byrd R, Stowe L, Windsor B, Smith-Whitley K. Streptococcus pneumoniae sepsis and meningitis during the penicillin prophylaxis era in children with sickle cell disease. J Pediatr Hematol Oncol. 2002;24:470-472.
    1. Horton DP, Ferriero DM, Mentzer WC. Nontraumatic fat embolism syndrome in sickle cell anemia. Pediatr Neurol. 1995;12:77-80.
    1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436.
    1. Hungerford DS. Response: the role of core decompression in the treatment of ischemic necrosis of the femoral head. Arthritis Rheum. 1989;32:801-806.
    1. Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, Visintainer P. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr. 1996;129:559-565.
    1. Jison ML, Gladwin MT. Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. Am J Respir Crit Care Med. 2003;168:3-4.
    1. Kar BC, Satapathy RK, Kulozik AE, Kulozik AE, Sirr M, Serjeant BE, Serjeant GR. Sickle cell disease in Orissa State, India. Lancet. 1986;2:1198-1201.
    1. Kirkham FJ, Calamante F, Bynevelt M, Gadian DG, Evans JP, Cox TC, Connelly A. Perfusion magnetic resonance abnormalities in patients with sickle cell disease. Ann Neurol. 2001;49:477-485.
    1. Konotey-Ahulu FID. Computer assisted analysis of data on 1,697 patients attending the sickle cell haemoglobinopathy clinic of Korle Bu Teaching Hospital. Accra, Ghana. Clinical features: I. Sex, genotype, age, rheumatism and dactylitis frequencies. Ghana Med J. 1971;10:241-260.
    1. Koshy M, Entsuah R, Koranda A, Kraus AP, Johnson R, Bellvue R, Flournoy-Gill, Z, Levy P. Leg ulcers in patients with sickle cell disease. Blood. 1989;74:1403-1408.
    1. Koshy M, Thomas C, Goodwin J. Vascular lesions in the central nervous system in sickle cell disease (neuropathology). J Assoc Acad Minor Phys. 1990;1:71-78.
    1. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved survival in homozygous sickle cell disease: lessons from a cohort study. Br Med J. 1995;311:160-162.
    1. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics. 1989;84:500-508.
    1. Maitre B, Habibi A, Roudot-Thoraval F, Bachir D, Belghiti DD, Galacteros F. Acute chest syndrome in adults with sickle cell disease. Chest. 2000;117:1386-1392.
    1. Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J, Shah AK, Mankad VN, and the Investigators of the Cooperative Study of Sickle Cell Disease. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123:359-365.
    1. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood. 2001;98:1955-1962.
    1. McBurney PG, Hanevold CD, Hernandez CM, Waller JL, McKie KM. Risk factors of microalbuminuria in children with sickle cell anemia. J Pediatr Hematol Oncol. 2002;24:473-477.
    1. McKerrell TD, Cohen HW, Billett HH. The older sickle cell patient. Am J Hematol. 2004;76:101-106.
    1. Milner PF, Kraus AP, Sebes JI, Sleeper LA, Dukes KA, Embury SH, Bellevue R, Koshy M, Moohr JW, Smith J. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325:1476-1481.
    1. Morris CR, Morris SM, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vinchinsky EP. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168:63-69.
    1. O'Brien KL, Swift AJ, Winkelstein JA, Santosham M, Stover B, Luddy R, Gootenberg JE, Nold JT, Eskenazi A, Snader SJ, Lederman HM. Safety and immunogeniecity of heptavalent pneumococcal vaccine conjugated to CRM197 among infants with sickle cell disease. Pediatrics. 2000;106:965-972.
    1. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288-294.
    1. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.
    1. Pegelow CH, Macklin EA, Moser FG, Wang WC, Bello JA, Miller ST, Vichinsky EP, DeBaun MR, Guarini L, Zimmerman RA, Younkin DP, Gallagher DM, Kinney TR. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood. 2002;99:3014-3018.
    1. Pelton SI, Klein JO. The future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases in infants and children. Pediatrics. 2002;110:805-814.
    1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644.
    1. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325:11-16.
    1. Powars DR. Sickle cell anemia and major organ failure. Hemoglobin. 1990;14:573-98.
    1. Powars D, Chan LS, Schroeder WA. The variable expression of sickle cell disease is genetically determined. Semin Hematol. 1990;27:1-18.
    1. Powars D, Overturf G, Weiss J, Lee S, Chan L. Pneumococcal septicemia in children with sickle cell anemia: changing trend of survival. JAMA. 1981;245:1839-1842.
    1. Powars D, Weidman JA, Odom-Maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore). 1988;67:66-76.
    1. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med. 1978;65:461-471.
    1. Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors. Am J Hematol. 2002;70:206-215.
    1. Powars DR, Elliott-Mills DD, Chan L, Niland J, Hiti AL, Opas LM, Johnson C. Chronic renal failure in sickle cell disease. Risk factors, clinical course and mortality. Ann Intern Med. 1991;115:614-620.
    1. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004;103:4023-4027.
    1. Rogers DW, Clarke JM, Cupidore L, Ramlal A, Sparke BR, Serjeant GR. Early deaths in Jamaican children with sickle cell disease. Br Med J. 1978;1:1515-1516.
    1. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
    1. Saito S, Saito M, Nishina T, Ohzono K, Ono K. Long-term results of total hip arthroplasty for osteonecrosis of the femoral head. A comparison with osteoarthritis. Clin Orthop Relat Res. 1989;244:198-207.
    1. Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman R, DeSimone J. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 2003;102:3865-3870.
    1. Sharpsteen JR, Powars D, Johnson C, Rogers ZR, Williams WD, Posch RJ. Multisystem damage associated with tricorporal priapism in sickle cell disease. Am J Med. 1993;94:289-295.
    1. Steen RG, Emudianughe T, Hankins GM, Wynn LW, Wang WC, Xiong X, Helton KJ. Brain imaging findings in pediatric patients with sickle cell disease. Radiology. 2003;228:216-225.
    1. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. Risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645-1651.
    1. Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood. 1999;94:1555-1560.
    1. Stulberg BN, Bauer TW, Belhobek GH. Making core decompression work. Clin Orthop Relat Res. 1990;261:186-195.
    1. Vermylen C. Hematopoietic stem cell transplantation in sickle cell disease. Blood Rev. 2003;17:163-166.
    1. Vichinsky E, Hurst D, Earles A, Kleman K, Lubin B. Newborn screening for sickle cell disease: effect on mortality. Pediatrics. 1988;81:749-755.
    1. Walker TM, Hambleton IR, Serjeant GR. Gallstones in sickle cell disease: observations from the Jamaican Cohort Study. J Pediatr. 2000;136:80-85.
    1. Walters MC, Nienhuis AW, Vichinsky E. Novel therapeutic approaches in sickle cell disease. Hematology (Am Soc Hematol Educ Program). 2002;10-34.
    1. Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, Buchanan GE, Rogers ZR, Dinndorf P, Davies SC, Roberts IA, Dickerhoff R, Yeager AM, Hsu L, Kurtzberg J, Ohene-Frempong K, Bunin N, Bernaudin F, Wong WY, Scott JP, Margolis D, Vichinsky E, Wall DA, Wayne AS, Pegelow C, Redding-Lallinger R, Wiley J, Klemperer M, Mentzer WC, Smith FO, Sullivan KM. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000;95:1918-1924.
    1. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001;139:790-796.
    1. Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99:10-14.
    1. Weiner DL, Brugnara C. Hydroxyurea and sickle cell disease. A chance for every patient. JAMA. 2003;289:1692-1694.
    1. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle cell disease in Jamaica: a clinic based population study. Lancet. 2001;357:680-683.
    1. Witt O, Monkemeyer S, Ronndahl G, Erdlenbruch B, Reinhardt D, Kanbach K, Pekrun A. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood. 2003;101:2001-2007.
    1. Wong WY, Powars DR, Chan L, Hiti A, Johnson C, Overturf G. Polysaccharide encapsulated bacterial infection in sickle cell anemia: a thirty year epidemiologic experience. Am J Hematol. 1992;39:176-182.
    1. Woodard P, Jeng M, Handgretinger R, Wang W, Cunningham J. Summary of symposium: the future of stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol. 2002;24:512-514.
    1. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103:2039-2045.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する